We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel.
- Recent GMDA Stock Price: $1.72
- Yearly Gain for GMDA stock: -70.07%
- Market Cap for GMDA stock: $103.17M
- P/E Ratio for GMDA stock: -1.038
Will GMDA's stock price go up? Is there an accurate GMDA stock forecast available?
TipRanks.com reports that Gamida Cell currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $13.60. The target pricing ranges from a high GMDA forecast of $22.00 down to a low forecast of $6.00. Gamida Cell (GMDA)’s last closing stock price was $1.72 which would put the average price target at 690.70% upside.
In addition, TradingView issued a n/a rating for GMDA stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on GMDA stock.
Other analysts covering GMDA include:
- Jason Butler of JMP Securities issued a Buy rating with the price target of $ 17 on 2 days ago
- Gil Blum of Needham issued a Buy rating with the price target of $ 12 on 2 days ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $ 6 on 2 months ago
- Matthew Cross of Alliance Global Partners issued a Buy rating with the price target of $ 11 on 2 months ago
If you are wondering if GMDA is a good stock to buy, here are 3rd party ratings for GMDA stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 31% (77 out of 252)
What is the sentiment on the street regarding Gamida Cell? (Current ratings compiled by TipRanks.com)
- News Sentiment for GMDA stock: Very Bullish
- Blogger Consensus for GMDA stock: Bullish
- Media Buzz for GMDA stock: Very High
- Insider Signal for GMDA stock: ―
- Investor Sentiment for GMDA stock: Negative
- Hedge Fund signal for GMDA stock: Positive
The stock market is extremely volatile, and you need to do your own research on GMDA stock including scouring the social networks like GMDA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for GMDA stock chart >>
Summary: TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts.
- Recent TMDX Stock Price: $37.28
- Yearly Gain for TMDX stock: 33.52%
- Market Cap for TMDX stock: $1.04B
- P/E Ratio for TMDX stock: -24.629
Will TMDX's stock price go up? Is there an accurate TMDX stock forecast available?
TipRanks.com reports that TransMedics Group currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $47.00. The target pricing ranges from a high TMDX forecast of $58.00 down to a low forecast of $34.00. TransMedics Group (TMDX)’s last closing stock price was $37.28 which would put the average price target at 26.07% upside.
In addition, TradingView issued a Buy rating for TMDX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TMDX stock.
Other analysts covering TMDX include:
- Allen Gong of J.P. Morgan issued a Buy rating with the price target of $ 48 on 1 day ago
- William Plovanic of Canaccord Genuity issued a Buy rating with the price target of $ 58 on 1 day ago
- Josh Jennings of Cowen & Co. issued a Buy rating with the price target of $ 50 on 1 day ago
- Cecilia Furlong of Morgan Stanley issued a Hold rating with the price target of $ 34 on 1 month ago
If you are wondering if TMDX is a good stock to buy, here are 3rd party ratings for TMDX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 37% (94 out of 252)
What is the sentiment on the street regarding TransMedics Group? (Current ratings compiled by TipRanks.com)
- News Sentiment for TMDX stock: Neutral
- Blogger Consensus for TMDX stock: Neutral
- Media Buzz for TMDX stock: Very Low
- Insider Signal for TMDX stock: ―
- Investor Sentiment for TMDX stock: Very Positive
- Hedge Fund signal for TMDX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on TMDX stock including scouring the social networks like TMDX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TMDX stock chart >>
Summary: ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.
- Recent AVXL Stock Price: $10.34
- Yearly Gain for AVXL stock: -44.96%
- Market Cap for AVXL stock: $800.41M
- P/E Ratio for AVXL stock: -17.075
Will AVXL's stock price go up? Is there an accurate AVXL stock forecast available?
TipRanks.com reports that Anavex Life Sciences currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $35.20. The target pricing ranges from a high AVXL forecast of $42.00 down to a low forecast of $19.00. Anavex Life Sciences (AVXL)’s last closing stock price was $10.34 which would put the average price target at 240.43% upside.
In addition, TradingView issued a Sell rating for AVXL stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AVXL stock.
Other analysts covering AVXL include:
- Ram Selvaraju of H.C. Wainwright issued a Buy rating with the price target of $ 42 on 1 day ago
- Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 40 on 2 days ago
- Yun Zhong of BTIG issued a Buy rating with the price target of $ 35 on 2 days ago
- Jason Kolbert of Dawson James issued a Buy rating with the price target of $ 19 on 1 month ago
If you are wondering if AVXL is a good stock to buy, here are 3rd party ratings for AVXL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (77 out of 252)
What is the sentiment on the street regarding Anavex Life Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for AVXL stock: Very Bullish
- Blogger Consensus for AVXL stock: Bullish
- Media Buzz for AVXL stock: Medium
- Insider Signal for AVXL stock: Neutral
- Investor Sentiment for AVXL stock: Neutral
- Hedge Fund signal for AVXL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AVXL stock including scouring the social networks like AVXL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AVXL stock chart >>
Summary: Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).
- Recent ESPR Stock Price: $5.87
- Yearly Gain for ESPR stock: -58.86%
- Market Cap for ESPR stock: $369.85M
- P/E Ratio for ESPR stock: -0.921
Will ESPR's stock price go up? Is there an accurate ESPR stock forecast available?
TipRanks.com reports that Esperion currently has 8 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $10.00. The target pricing ranges from a high ESPR forecast of $22.00 down to a low forecast of $3.00. Esperion (ESPR)’s last closing stock price was $5.87 which would put the average price target at 70.36% upside.
In addition, TradingView issued a Sell rating for ESPR stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ESPR stock.
Other analysts covering ESPR include:
- Serge Belanger of Needham issued a Buy rating with the price target of $ 12 on 1 day ago
- Joseph Thome of Cowen & Co. issued a Buy rating with the price target of $ 13 on 1 day ago
- Jason Butler of JMP Securities issued a Buy rating with the price target of $ 11 on 1 day ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 22 on 1 day ago
If you are wondering if ESPR is a good stock to buy, here are 3rd party ratings for ESPR stock:
- TipRanks.com: Hold
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 32% (81 out of 252)
What is the sentiment on the street regarding Esperion? (Current ratings compiled by TipRanks.com)
- News Sentiment for ESPR stock: Bullish
- Blogger Consensus for ESPR stock: Bullish
- Media Buzz for ESPR stock: Very High
- Insider Signal for ESPR stock: Negative
- Investor Sentiment for ESPR stock: Very Negative
- Hedge Fund signal for ESPR stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ESPR stock including scouring the social networks like ESPR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ESPR stock chart >>
Summary: Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
- Recent BPMC Stock Price: $56.29
- Yearly Gain for BPMC stock: -34.54%
- Market Cap for BPMC stock: $3.35B
- P/E Ratio for BPMC stock: -4.58
Will BPMC's stock price go up? Is there an accurate BPMC stock forecast available?
TipRanks.com reports that Blueprint Medicines currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $81.75. The target pricing ranges from a high BPMC forecast of $152.00 down to a low forecast of $40.00. Blueprint Medicines (BPMC)’s last closing stock price was $56.29 which would put the average price target at 43.90% upside.
In addition, TradingView issued a Buy rating for BPMC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BPMC stock.
Other analysts covering BPMC include:
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $ 152 on 8 hours ago
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $ 100 on 8 hours ago
- Dane Leone of Raymond James issued a Buy rating with the price target of $ 115 on 1 day ago
- Christopher Raymond of Piper Sandler issued a Hold rating with the price target of $ 59 on 1 day ago
If you are wondering if BPMC is a good stock to buy, here are 3rd party ratings for BPMC stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 31% (77 out of 252)
What is the sentiment on the street regarding Blueprint Medicines? (Current ratings compiled by TipRanks.com)
- News Sentiment for BPMC stock: Very Bullish
- Blogger Consensus for BPMC stock: ―
- Media Buzz for BPMC stock: Medium
- Insider Signal for BPMC stock: Negative
- Investor Sentiment for BPMC stock: Positive
- Hedge Fund signal for BPMC stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on BPMC stock including scouring the social networks like BPMC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BPMC stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================